Filtered By:
Specialty: Hematology
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 643 results found since Jan 2013.
Management of tandem occlusions in patients who receive rtPA
ConclusionThe use of GP2b3aI in the setting of tandem occlusions that required emergent stent placement post-rtPA appears safe and effective. Given the small sample size, these findings should be interpreted cautiously, and need to be confirmed in a larger patient population.
Source: Journal of Thrombosis and Thrombolysis - June 23, 2021 Category: Hematology Source Type: research
Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics
Atrial fibrillation (AF) confers the major risk for ischemic stroke and systemic embolism [1]. Although anticoagulants can reduce the risk of AF-associated stroke, thromboembolic events, and mortality [2,3], a major drawback is the increased the risk of bleeding [4,5]. The overall risks and benefits must be carefully considered when selecting the most appropriate antithrombotic therapy, and for this reason, accurate bleeding risk stratification is needed. In clinical practice, various bleeding risk scores have been proposed and validated to assess the risk of bleeding in AF patients receiving oral anticoagulants (OAC).
Source: Thrombosis Research - November 8, 2021 Category: Hematology Authors: Sun Young Choi, Moo Hyun Kim, Sung-Cheol Yun Tags: Letter to the Editors-in-Chief Source Type: research
Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study
AbstractStroke is the third leading cause of death in the United States and the leading cause of adult disability. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. Unfortunately, only 1 –3% of stroke patients in the US receive this therapy because of the narrow time window and severe side effects for using tPA. The most deadly and damaging side effect is the risk of intracranial bleeding or hemorrhage. For that reason, the dose of tPA and its overall administration are under tigh t control, which may com...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2021 Category: Hematology Source Type: research
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients
AbstractFactor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial infarction, particularly at high doses. This was a retrospective, single-center, cohort investigation that included patients who received a weight-based dose of aPCC for reversal of apixaban and rivaroxaban between Jan...
Source: Journal of Thrombosis and Thrombolysis - November 17, 2021 Category: Hematology Source Type: research
Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study
AbstractStroke is the third leading cause of death in the United States and the leading cause of adult disability. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. Unfortunately, only 1 –3% of stroke patients in the US receive this therapy because of the narrow time window and severe side effects for using tPA. The most deadly and damaging side effect is the risk of intracranial bleeding or hemorrhage. For that reason, the dose of tPA and its overall administration are under tigh t control, which may com...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2021 Category: Hematology Source Type: research
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients
This study compares the safety and efficacy profiles of DP-DES and BP-DES based on short-term (1–3 months), intermediate-term (4–6 months) and standard DAPT (6–12 months) durations. A searc h was conducted on Embase and Medline for Randomized Controlled Trials (RCTs) comparing stent types, and DAPT durations. Primary endpoints include cardiac death, myocardial infarction (MI), definite stent thrombosis, stroke, target vessel revascularization (TVR) and major bleeding. Network analysis was conducted to summarize the evidence. A total of 15 RCTs involving 43,875 patients were included. DP-DES was associated with sig...
Source: Journal of Thrombosis and Thrombolysis - January 4, 2022 Category: Hematology Source Type: research
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients
This study was designed to explore the prevalence of recommended anticoagulation by guidelines before admission and its impact on the incidence of acute myocardial infarction (AMI) and the AMI associated in-hospital outcomes in patients with atrial fibrillation (AF). 10,725 patients with AF at their first hospitalizations in our hospitals were retrospectively reviewed, with a prevalence of recommended anticoagulation preadmission 24.41% (Number = 2618). They had lower risk of AMI incidence (Adjusted OR 0.66, 95%CI 0.54 –0.81, p < 0.001) compared to those without recommended anticoagulation after multivariate logist...
Source: Journal of Thrombosis and Thrombolysis - January 24, 2022 Category: Hematology Source Type: research
Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry
AbstractSymptomatic intracranial hemorrhage (SICH) is a catastrophic complication of endovascular treatment (EVT) for large vessel occlusion (LVO). We aimed to investigate the incidence and predictors of SICH after EVT. Patients were selected from the ANGEL-ACT registry. We diagnosed SICH according to the Heidelberg Bleeding Classification. Logistic regression analyses were performed to determine the independent predictors of SICH. Of the 1283 patients, SICH was observed in 116 patients (9.0%). On multivariable analysis, admission National Institutes of Health Stroke Scale (NIHSS) > 12 (odds ratio [OR] = 1.86,...
Source: Journal of Thrombosis and Thrombolysis - August 1, 2022 Category: Hematology Source Type: research
Clinical Outcomes of Prolonged Antiplatelet Therapy after Percutaneous Coronary Intervention in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
Conclusions: Prolonged DAPT might decrease the risk of mortality, MACE, and stroke in patients with CKD without any significant difference in bleeding or revascularization. Additional studies are required to determine whether long-term DAPT could be considered for most CKD patients after PCI.Blood Purif
Source: Blood Purification - December 6, 2022 Category: Hematology Source Type: research
Frailty and subsequent adverse outcomes in older patients with atrial fibrillation treated with oral anticoagulants: The Shizuoka study
CONCLUSION: Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.PMID:37168397 | PMC:PMC10165150 | DOI:10.1016/j.rpth.2023.100129
Source: Thrombosis and Haemostasis - May 11, 2023 Category: Hematology Authors: Shiori Nishimura Hiraku Kumamaru Satoshi Shoji Eiji Nakatani Hiroyuki Yamamoto Nao Ichihara Alexander T Sandhu Yoshiki Miyachi Hiroaki Miyata Shun Kohsaka Source Type: research
Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease
ConclusionAmong patients with AF and AKD, DOACs were linked to a lower risk of ischemic events, and apixaban was linked to a lower risk of any ischemia and any bleeding than warfarin.
Source: Journal of Thrombosis and Thrombolysis - July 15, 2023 Category: Hematology Source Type: research
